【个人简介】

朱爱如，博士，南山学者骨干人才，教授。本硕毕业于四川大学，2021年博士毕业于广州医科大学；2021年-2025年于广州医科大学附属第一医院/呼吸疾病全国重点实验室从事博士后研究工作；2025年全职加入广州医科大学附属第一医院/广州呼吸健康研究院/呼吸疾病全国重点实验室工作。

专注于呼吸道病毒感染与疫苗接种人群的黏膜免疫与外周免疫机制研究，主要研究成果包括揭示呼吸道黏膜T细胞在新冠病毒清除中的核心作用，阐明其与外周T细胞的差异特征，发现肌注疫苗难以诱导黏膜记忆。通过MERS-CoV特异性T细胞应答首次证实非洲单峰驼密接人群存在隐匿感染，揭示动物-人跨种传播链，指导MERS监测，填补重要病原体传播机制空白。构建新冠、MERS及低冠（229E/NL63）小鼠模型等动物模型，参与制定《新冠病毒抗原特异性T细胞检测专家共识》，推动疫苗药物评价标准化。近5年以第一/通讯作者（含共同）发表论文21篇，10篇IF>10，包括Nat Immunol（2025, 2024）、Lancet Infect Dis（2021）、Cell（2020）、STTT（2023a, b）、PNAS（2023）、Emerg Microbes Infect（2020）、Adv Sci （2023）、Cell Discov（2024）等。

【研究方向】

研究方向聚焦新发突发病毒感染与疫苗接种人群，阐明不同呼吸道病原感染与疫苗接种诱导的呼吸道黏膜免疫的共性规律和个性特征；呼吸道黏膜免疫应答的关键调控因子及其调控机制。

【科研项目】

1. 国家自然科学基金委员会, 青年科学基金项目, 82201933, 肺内新冠病毒特异性T细胞应答在疾病转归中的作用及机制研究, 2023-01-01 至 2025-12-31, 30万元, 在研, 主持

2. 呼吸疾病全国重点实验室自主课题，SKLRD-Z-202330，肺内新冠病毒特异性T细胞应答在疾病转归中的作用及机制研究，2023-01至2025-12，20万元，在研，主持

3. 中国博士后科学基金面上项目，新冠患者肺部病毒特异性T细胞应答的规律与作用机制研究，2022M710892，2023-01至2024-12，8万元，在研，主持

4. 国家自然科学基金委员会, 面上项目, 82172240, 新冠患者和疫苗免疫者体液免疫应答多维动态分析及与保护效果量效关系研究, 2022-01-01 至 2025-12-31, 55万元, 在研, 参与

5. 国家重点研发计划, 2022YFC2303700，冠状病毒入侵后共性机制与广谱性干预靶点研究，2023-01 至 2025-12，120万，在研，参与（子任务负责人）

【代表性论文及著作】

1. Zhu A^#, Chen Z^#, Yan Q^#, Jiang M^#, Liu X^#, Li Z^#, Li N^#, Tang C^#, Jian W^#, He J, Chen L, Cheng J, Chen C, Tang T, Xu Z, Hu Q, Li F, Wang Y, Sun J, Zhuang Z, Wen L, Zhuo J, Liu D, Zhang Y, Huang X, Li S, Zeng Q, Chen F, Zhou L, Liu D, Zhong C, Chen Y, Li S, Liang K, Zhong N, Zhang X, Chen J, Chen X*, Xu Y*, Zhong N*, Zhao J*, Zhao J*. Robust mucosal SARS-CoV-2-specific T cells effectively combat COVID-19 and establish polyfunctional resident memory in patient lungs. Nat Immunol. 2025 Jan 28. doi: 10.1038/s41590-024-02072-9. Epub ahead of print. (IF=27.7)

2. Chen C^#, Tang T^#, Chen Z^#, Chen L, Cheng J, Li F, Sun J, Zhao J, Wang Y, Yan Q*, Zhao J*, Zhu A*. Antibody dynamics for heterologous boosters with aerosolized Ad5-nCoV following inactivated COVID-19 vaccines. Hum Vaccin Immunother. 2024 Dec 31;20(1):2423466. (IF=4.1)

3. Zhu A^#, Zhou L^#, Chen Z, Liu D, Feng H, Cai B, Chen X, Zhao J, Zhao J, Chen J, Li M*, He J*. Single-cell analysis reveals T cell dysfunction driven by macrophages and differential expression of transposable elements in severe COVID-19 patients. Heliyon. 2024 Sep 27;10(19):e38688. (IF=3.4)

4. He X^#, Zhang X^#, Wu B^#, Deng J^#, Zhang Y^#, Zhu A^#, Yuan Y, Lin Y, Chen A, Feng J, Wang X, Wu S, Liu Y, Liu J, Wang Y, Li R, Liang C, Yuan Q, Liang Y, Fang Q, Xi Z, Li W, Liang L, Zhang Z, Tang H, Peng Y, Ke C, Ma X, Cai W, Pan T, Liu B, Deng K, Chen J, Zhao J*, Wei X*, Chen R*, Zhang Y*, Zhang H*. The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis. Nat Immunol. 2024 Apr;25(4):622-632. (IF=27.7)

5. Li Y^#, Tang Y^#, Wang X^#, Zhu A^#, Liu D^#, He Y^#, Guo H, Zheng J, Liu X, Chi F, Wang Y, Zhuang Z, Zhang Z, Liu D, Chen Z, Li F, Ran W, Yu K, Wang D, Wen L, Zhuo J, Zhang Y, Xi Y, Zhao J*, Zhao J*, Sun J*. Characterization of humoral immune responses against SARS-CoV-2 accessory proteins in infected patients and mouse model. Virol Sin. 2024 Jun;39(3):414-421. (IF=4.3)

6. Chen Z^#, Yuan Y^#, Hu Q^#, Zhu A^#, Chen F, Li S, Guan X, Lv C, Tang T, He Y, Cheng J, Zheng J, Hu X, Zhao J*, Zhao J*, Sun J*. SARS-CoV-2 immunity in animal models. Cell Mol Immunol. 2024 Feb;21(2):119-133. (IF=21.8)

7. Zhao H^#, Zhang NN^#, Hannawi S^#, Zhu AR^#, Xiong XC, Huang YJ, Yu DD, Chen CJ, Dai J, Abuquta A, Ying B*, Zhao JC*, Qin CF*. Neutralization of Omicron XBB.1 by booster vaccination with BA.4/5 monovalent mRNA vaccine. Cell Discov. 2024 Jan 9;10(1):7. (IF=13.0)

8. Zhang J^#, Zhu A^#, Mei M, Qu J, Huang Y, Shi Y, Xue M, Zhang J, Zhang R*, Zhou B*, Tan X*, Zhao J*, Wang Y*. Repurposing CRISPR/Cas to Discover SARS-CoV-2 Detecting and Neutralizing Aptamers. Adv Sci (Weinh). 2023 Aug;10(22):e2300656. (IF=14.3)

9. Zhu A^#, Wei P^#, Man M^#, Liu X^#, Ji T^#, Chen J, Chen C, Huo J*, Wang Y*, Zhao J*. Antigenic characterization of SARS-CoV-2 Omicron subvariants XBB.1.5, BQ.1, BQ.1.1, BF.7 and BA.2.75.2. Signal Transduct Target Ther. 2023 Mar 15;8(1):125. (IF=40.8)

10. Qiu S^#, Chen Z^#, Zhu A^#, Zeng Q^#, Liu H^#, Liu X, Ye F, Jin Y, Wu J, Yang C, Wang Q, Chen F, Chen L, Tian S, Du X, Hu Q, Cheng J, Chen C, Li F, Sun J, Wang Y, Zhao J*, Zhao J*, Song H*. Successful clearance of persistent SARS-CoV-2 asymptomatic infection following a single dose of Ad5-nCoV vaccine. Signal Transduct Target Ther. 2023 Mar 15;8(1):123. (IF=40.8)

11. Liu D^#, Chen C^#, Chen D^#, Zhu A^#, Li F^#, Zhuang Z, Mok CKP, Dai J, Li X, Jin Y, Chen Z, Sun J, Wang Y, Li Y, Zhang Y, Wen L, Zhang Z, Zhuo J, Wang J, Ran W, Wang D, Zhang S, Tang Y, Li S, Lai X, Wei P, Yuan J, Chen F, Huang S, Sun F, Qian Z, Tan W, Zhao J*, Peiris M*, Zhao J*. Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2. Proc Natl Acad Sci U S A. 2023 Jan 24;120(4):e2202820120. (IF=9.4)

12. Liao B^#, Chen Z^#, Zheng P^#, Li L^#, Zhuo J, Li F, Li S, Chen D, Wen C, Cai W, Wu S, Tang Y, Duan L, Wei P, Chen F, Yuan J, Yang J, Feng J, Zhao J, Zhao J*, Sun B*, Zhu A*, Li Y*, Tang X*. Detection of Anti-SARS-CoV-2-S2 IgG Is More Sensitive Than Anti-RBD IgG in Identifying Asymptomatic COVID-19 Patients. Front Immunol. 2021 Aug 19;12:724763. (IF=5.7)

13. Mok CKP^#, Zhu A^#, Zhao J^#, Lau EHY, Wang J, Chen Z, Zhuang Z, Wang Y, Alshukairi AN, Baharoon SA, Wang W, Tan W, Liang W, Oladipo JO, Perera RAPM, Kuranga SA, Peiris M*, Zhao J*. T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study. Lancet Infect Dis. 2021 Mar;21(3):385-395. (IF=36.4)

14. Sun J^#, Zhu A^#, Li H^#, Zheng K^#, Zhuang Z^#, Chen Z^#, Shi Y^#, Zhang Z^#, Chen SB^#, Liu X^#, Dai J, Li X, Huang S, Huang X, Luo L, Wen L, Zhuo J, Li Y, Wang Y, Zhang L, Zhang Y, Li F, Feng L, Chen X, Zhong N, Yang Z*, Huang J*, Zhao J*, Li YM*. Isolation of Infectious SARS-CoV-2 from Urine of a COVID-19 Patient. Emerg Microbes Infect. 2020 Apr 28:1-8. (IF=8.4)

15. Airu Zhu^#, Zhao Chen, Yanqun Wang, Qiuhui Zeng, Jing Sun, Zhen Zhuang, Fang Li, Jingxian Zhao, Jincun Zhao*, Nanshan Zhong*, Immune responses to SARS-CoV-2 infection in Humans and ACE2 humanized mice. Fundamental Research 1 (2021) 124–130.

16. Fang ZF^#, Sun BQ^#, Zhu AR^#, Lin LC, Zhao JC, He S, Huang SK, Zhong NS, Liu ZG. Multiplexed analysis of circulating IgA antibodies for SARS-CoV-2 and common respiratory pathogens in COVID-19 patients. J Med Virol. 2021 May;93(5):3257-3260. (IF=6.8)

17. Zhong H^#, Wang Y^#, Shi Z^#, Zhang L^#, Ren H^#, He W^#, Zhang Z^#, Zhu A^#, Zhao J^#, Xiao F^#, Yang F, Liang T, Ye F, Zhong B, Ruan S, Gan M, Zhu J, Li F, Li F, Wang D, Li J, Ren P, Zhu S, Yang H, Wang J, Kristiansen K, Tun HM, Chen W, Zhong N, Xu X, Li YM, Li J, Zhao J. Characterization of respiratory microbial dysbiosis in hospitalized COVID-19 patients. Cell Discov. 2021 Apr 13;7(1):23. (IF=13.0)

18. Lu W^#, Liu X^#, Wang T^#, Liu F^#, Zhu A^#, Lin Y^#, Luo J, Ye F, He J, Zhao J, Li Y, Zhong N. Elevated MUC1 and MUC5AC mucin protein levels in airway mucus of critical ill COVID-19 patients. J Med Virol. 2021 Feb;93(2):582-584. (IF=6.8)

19. Zhang Z^#, Wang T^#, Liu F^#, Zhu A^#, Gu G^#, Luo J, Xu J, Zhao J, Li Y, Li Y, Liu X*, Zhong N*, Lu W*. The proteomic characteristics of airway mucus from critical ill COVID-19 patients. Life Sci. 2021 Jan 14; 269:119046. (IF=5.2)

20. Sun J^#, Zhuang Z^#, Zheng J^#, Li K^#, Wong RL^#, Liu D^#, Huang J^#, He J^#, Zhu A^#, Zhao J^#, Li X^#, Xi Y^#, Chen R, Alshukairi AN, Chen Z, Zhang Z, Chen C, Huang X, Li F, Lai X, Chen D, Wen L, Zhuo J, Zhang Y, Wang Y, Huang S, Dai J, Shi Y, Zheng K, Leidinger MR, Chen J, Li Y, Zhong N, Meyerholz DK, McCray PB Jr*, Perlman S*, Zhao J*. Generation of a Broadly Useful Model for COVID-19 Pathogenesis, Vaccination, and Treatment. Cell. 2020 Jun 10:S0092-8674(20)30741-8. (IF=45.5)

21. Wang Y^#, Sun J^#, Li X^#, Zhu A^#, Guan W^#, Sun DQ^#, Gan M, Niu X, Dai J, Zhang L, Zhang Z, Shi Y, Huang S, Mok CKP, Yang Z, Wang Z, Tan W, Li Y, Chen L, Chen R, Peiris M, Zhong N, Zhao J, Huang J*, Zhao J*. Increased Pathogenicity and Virulence of Virus in Middle East Respiratory Syndrome Coronavirus Clade B in Vitro and in Vivo. J Virol. 2020 Jul 16;94(15):e00861-20. (IF=4.0)